SecBot SecBot

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

H.R. 1492 Rep. Gregory Murphy (R-NC-3) In committee
Bill text PDF
  1. Introduced Feb 21
  2. Committee Feb 21
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Feb 21, 2025Next: House vote
614d ago Feb 21, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
16companies, 125 filings
Subscribe to see spend
Member trades
26trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

16 companies
Companies by sector
Biotech & Pharma 16
Search all 16 companies, their asks and price moves Subscribe

Summary

This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.

Full summary3 paragraphs

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.

The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation.

The bill's changes apply retroactively.

Library of Congress summary, Feb 21, 2025

Summary versions
  • Introduced in HouseFeb 21, 2025

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.